• TechCrunch
• CrunchBase
• More
  • TechCrunch Europe
  • TechCrunch France
  • TechCrunch Japan

Pervasis Therapeutics

edit

Pervasis Therapeutics is a clinical stage company developing a broad portfolio of biologically active therapeutics. Building on its deep understanding of the specialized role that the endothelium plays in regulating natural healing and repair processes associated with disease, Pervasis is advancing groundbreaking new therapies to dramatically improve the outcomes of common vascular interventions, such as arteriovenous access, angioplasties, stents, and peripheral and coronary bypass grafts – the failure of which result in serious complications and a significant increase in medical costs.

Recent Milestones

edit

• 
  Pervasis Therapeutics — won orphan drug designation from the European Commission for its lead drug Vascugel (3/1/11)
  Posted 3/2/11 at 5:11am via masshightech.com
• 
  Pervasis Therapeutics — The U.S. Food and Drug Administration has granted fast track review status to Cambridge biotech Pervasis Therapeutics Inc. for Vascugel, its lead drug program (2/8/11)
  Posted 2/9/11 at 3:37am via masshightech.com
• 
  Pervasis Therapeutics — expanding into oncology and considering additional financing from either a corporate partner or the venture capital community (1/20/11)
  Posted 1/24/11 at 7:08am via masshightech.com
• 
  Pervasis Therapeutics received $17.4M in Series C funding. (8/31/09)
  Posted 9/24/09 at 3:17pm via prnewswire.com
• 
  Pervasis Therapeutics received $9.75M in Venture Round funding. (1/15/08)
  Posted 12/19/09 at 2:53am via pervasistx.com
• 
  Pervasis Therapeutics received $17.4M in Series B funding. (8/26/05)
  Posted 7/2/10 at 4:22am
• 
  Pervasis Therapeutics added Ed Kania as Director.
  Posted 4/16/13 at 8:52am

Videos

Screenshots

edit

Above: Pervasis Therapeutics
Uploaded: 10/16/09

Sources

1. EDGAR [edit]
2. Pervasis Therapeutics Closes Additional $9.75 Million in Financing (pervasistx.com) [edit]
3. Pervasis Therapeutics Announces $17 Million in Financing and New Board Member (news.prnewswire.com) [edit]
Pervasis broadens to cancer therapeutics, eyes new financings (masshightech.com) [edit]
Pervasis hemodialysis treatment lands FDA fast-track review (masshightech.com) [edit]
Pervasis drug candidate gets EU orphan drug status (masshightech.com) [edit]